What did the FDA approve for zanubrutinib in CLL/SLL in 2023?
In 2023, the FDA approved zanubrutinib (Brukinsa) for treating certain patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The approval is part of the drug’s labeled uses for B-cell malignancies and builds on earlier approvals for CLL/SLL. [1][2]
What was the approval date and label wording in 2023?
The exact 2023 approval date and the precise eligibility criteria depend on the specific FDA action (for example, whether it was a new indication, a change in line of therapy, or an expanded patient population). FDA labeling and the prescribing information are the sources that specify which subgroup(s) and what combination or prior-treatment status the approval covered. [1][2]
What CLL/SLL patients are covered by the 2023 approval?
CLL/SLL indications typically specify one or more of the following elements in the label: prior therapy status (treatment-naive vs. previously treated), whether the disease is relapsed/refractory, and whether the drug is used as monotherapy or with another agent. To match the 2023 decision accurately, the label section “Indications and Usage” in the FDA-approved prescribing information should be used. [1][2]
How does zanubrutinib fit into the CLL/SLL treatment landscape?
Zanubrutinib is a BTK inhibitor used in CLL/SLL. In clinical practice, BTK inhibitors are used across different lines of therapy depending on patient and disease factors, and they are often compared with other BTK inhibitors (such as ibrutinib and acalabrutinib) in both frontline and relapsed settings. The exact place for zanubrutinib depends on the FDA label and how it aligns with guideline-based sequencing. [1][2]
Where can I verify the 2023 FDA approval details?
The most reliable place to verify the 2023 approval (including the date, indication wording, and covered patient populations) is:
- The FDA’s official prescribing information/label for zanubrutinib (Brukinsa) [1]
- The FDA page or label archive that documents approval actions and labeling updates [2]
If you tell me whether you mean the initial CLL/SLL approval in 2019 or a specific 2023 expansion (and whether it was for treatment-naive, relapsed/refractory, or a combination), I can pinpoint the exact 2023 label language.
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212283
- https://www.accessdata.fda.gov/drugsatfda_docs/label/